Cannabis vs Psilocybin: The Neuroscience
Two of the most famous mind-altering plants, two entirely different systems - THC's CB1 dampening versus psilocybin's 5-HT2A excitation. Mechanism, dependence, neuroplasticity, 2026 evidence, and the law.
Kanna (Sceletium tortuosum): The Neuroscience
How a fermented South African succulent calms the mind - the mesembrine alkaloids, a rare dual SERT and PDE4 mechanism, the amygdala-fMRI and cognition trials, and an honest, still-small evidence base.
Mescaline vs Psilocybin: The Neuroscience
Two ancient psychedelics - a phenethylamine cactus alkaloid and a tryptamine mushroom prodrug - meet at the 5-HT2A receptor. Potency, duration, the one head-to-head trial, 2026 clinical evidence, and safety.
Kava (Kavalactones): The Neuroscience
How kava's kavalactones calm anxiety through a non-benzodiazepine GABA-A mechanism - the six kavalactones and chemotype, the trials from KADSS to the negative K-GAD study, and the hepatotoxicity controversy, held honestly.
DMT vs 5-MeO-DMT: The Neuroscience
Two short tryptamines, one methoxy group apart, at opposite ends of the psychedelic experience: 5-HT2A visions and entities vs 5-HT1A ego-dissolution and the void. Mechanism, dosing, 2026 trials, and safety.
PCP (Phencyclidine): The Neuroscience
The failed anesthetic that became psychiatry's key to psychosis: open-channel NMDA blockade, the NMDA-hypofunction model of schizophrenia, the parvalbumin circuit, honest harms, and the line to ketamine.
Ibogaine vs Ketamine: The Neuroscience
A polypharmacological root-bark alkaloid for addiction vs a rapid NMDA-antagonist antidepressant. Mechanism, onset, evidence, cardiac vs bladder risk, and 2026 access.
DXM (Dextromethorphan): The Neuroscience
An OTC cough suppressant since 1958 that is also a dissociative NMDA antagonist and now the engine of the antidepressant Auvelity. Mechanism, the CYP2D6 story, and the real risks.
LSD vs DMT: The Neuroscience
Same 5-HT2A doorway, opposite kinetics: LSD is a molecule that won't let go of its receptor and runs for hours; DMT flares and is gone in minutes. Mechanism, imaging, 2026 trials, and safety.
2C-B: The Neuroscience
Shulgin's favorite phenethylamine sits between MDMA and LSD: contested 5-HT2 pharmacology, a famously steep dose-response, thin-but-growing evidence, and a supply contaminated by NBOMes.
Ketamine vs Nitrous Oxide: The Neuroscience
Two NMDA antagonists reach the same receptor by an injection and a breath: ketamine, an approved fast rescue with a maintenance problem, versus nitrous oxide, a promising but investigational near-instant candidate.
Kratom (Mitragynine): The Neuroscience
The traditional leaf is a weak, G-protein-biased, multi-target opioid; concentrated 7-OH is a different animal. Mechanism, dependence, hepatotoxicity, and the 2026 leaf/7-OH regulatory split, honestly.
MDMA vs Psilocybin: A Neuroscience Comparison
An empathogen and a psychedelic heal along two different fault lines: MDMA quiets fear to reprocess trauma; psilocybin loosens rigidity to lift depression. Mechanisms, 2026 trial status, safety, and legal access compared.
Nitrous Oxide Neuroscience: The NMDA Antagonist
The oldest anesthetic in the cabinet is also the fastest-acting NMDA antagonist we know: a molecule that can lift depression in an hour and quietly dismantle the spinal cord over months.
Ketamine vs Psilocybin: A Neuroscience Comparison
Two rapid-acting antidepressants, two opposite mechanisms - NMDA vs 5-HT2A. How ketamine and psilocybin compare on onset, durability, evidence, safety, and 2026 access.
The Neuroscience of THC: How Cannabis Works
THC works because it mimics anandamide and docks onto CB1 receptors your neurons already use. A neuroscience-first tour of how cannabis works, what the evidence supports, and where it stays contested.
Ayahuasca vs Psilocybin: The Neuroscience
Both ayahuasca and psilocybin end up at the serotonin 5-HT2A receptor — but one is a single-molecule prodrug and the other a two-plant MAOI hack. A neuroscience comparison of mechanism, clinical evidence, safety, and law.
Salvia Divinorum: The Kappa-Opioid Psychedelic
Salvinorin A ignores serotonin entirely, activating the kappa-opioid receptor to fracture reality for a few shattering minutes. The neuroscience of the only nitrogen-free psychedelic in common use.
Psilocybin vs LSD: The Neuroscience Compared
Same receptor, different molecules: psilocybin vs LSD on potency, duration, trials, and the law.
Amanita Muscaria: The Neuroscience
The famous red mushroom is a GABA-A deliriant, not a psychedelic — muscimol, ibotenic acid, toxicity, and myth.
MDMA vs Ketamine for PTSD: The Neuroscience Compared
Two drugs, opposite mechanisms: how MDMA and ketamine compare for PTSD on evidence, regulation, and risk.
Ibogaine: The Neuroscience
A root-bark alkaloid that can switch off opioid withdrawal overnight — and stop the heart.
MDMA: The Neuroscience
Not a classic psychedelic but an empathogen — a serotonin releaser that quiets the amygdala and floods the brain with oxytocin. The PTSD trials, the reopened critical period, and the 2024 FDA rejection.
Mescaline: The Neuroscience
The first psychedelic ever isolated — a peyote and San Pedro alkaloid that opened the 5-HT2A door a century before we understood the receptor. The oldest psychedelic, and the least studied.
Ketamine: The Neuroscience
A 1960s anesthetic that lifts depression in hours by blocking the NMDA receptor — the glutamate surge, the synapses it regrows, esketamine, and the debate over whether the dissociation is the medicine.
DMT: The Neuroscience
Active at a few millionths of a gram and lasting twelve hours, LSD is the most potent classical psychedelic — the 5-HT2A receptor “lid” that explains the long trip, the brain’s dissolved boundaries, and LSD’s clinical return through MM120.
LSD: The Neuroscience
Active at a few millionths of a gram and lasting twelve hours, LSD is the most potent classical psychedelic — the 5-HT2A receptor “lid” that explains the long trip, the brain’s dissolved boundaries, and LSD’s clinical return through MM120.
Ayahuasca: The Neuroscience of the Vine
Two Amazonian plants, neither psychoactive alone, become one of the most studied psychedelics on Earth — the DMT–MAOI synergy, the quieting of the default mode network, and the rapid-antidepressant trials.
5-MeO-DMT: The Neuroscience of the God Molecule
The most powerful psychedelic acts on a different receptor than all the others — the 5-HT1A mechanism, the fastest ego death, the ultra-rapid antidepressant trials, and the threatened toad behind the molecule.
Psychedelics and Neuroplasticity: Reopening the Brain's Critical Periods
Psychedelics reopen the developmental windows the brain seals after childhood. How a single dose rewires the adult brain — dendritic spines, the TrkB receptor, the reopened critical period — and why what happens next decides everything.
Psychedelics and Meditation: The Contemplative Neuroscience
Two of humanity's oldest technologies for transforming the mind act on the same brain system — the default mode network. How psilocybin and meditation both quiet the self, and what the data show when they are combined.
Psilocybin and Bipolar Disorder: The Field's Hardest Open Question
The first peer-reviewed psilocybin trial that did not exclude bipolar disorder posted MADRS −24 (Cohen d=4.08) and zero hypomanic switches. The exclusion has stood since 2006; the reasoning behind it has not caught up with the data.
Psilocybin and Parkinson's Disease: The Neuroscience of a Possible Disease-Modifying Therapy
The first psychedelic ever tested in a neurodegenerative disease. Bradley 2025 UCSF trial: −9.3 MADRS, −4.6 motor improvement, zero serious adverse events. α-synuclein silences TrkB; psilocin reactivates it. The cleanest disease-modifying logic chain in psychedelic neuroscience.
Veterans and Psilocybin: The Neuroscience of Healing the Wounds of War
22 veterans die by suicide every day. Combat trauma damages four neural systems at once — amygdala, default mode network, fear-extinction circuit, neuroinflammation. Psilocybin is the first intervention demonstrated to engage all four. The full master review on veterans + psilocybin science.
Psilocybin and Alzheimer’s Disease: The Neuroplasticity Hypothesis
BDNF collapses 30–40% in Alzheimer's brains. Psilocybin triggers the largest known BDNF surge. Tau phosphorylation fell ~35% in mouse models. Four mechanisms, one disease — the most unexpected convergence in neurodegeneration research.
The Pineal Gland: Science vs Myth
Descartes called it the seat of the soul. Strassman called it the DMT factory. Borjigin's lab found DMT-producing enzymes throughout the cortex — not just in the pineal. The neuroscience of the most mythologised organ in your skull.
5-MeO-DMT vs Psilocybin: Two Doors to the Same Room
Six hours vs fifteen minutes. Davis (2018) showed 5-MeO-DMT mystical intensity equals high-dose psilocybin. GH001 hit -15.5 MADRS in Phase 2b TRD. The pharmacology, phenomenology, and clinical data on two molecules that occasion mystical experiences of equivalent intensity.
Psilocybin and Nicotine Addiction: How a Single Session Breaks the Hardest Habit
80% quit rate after 2-3 sessions vs 13% for nicotine patches. Johns Hopkins researchers have cracked the neuroscience of tobacco addiction — and it starts with the default mode network.
Psilocybin and Anxiety: The Neuroscience of Dissolving Fear
80% of participants reported sustained anxiety relief after a single psilocybin session. The amygdala quiets, the default mode network resets, and fear patterns built over decades dissolve.
Psilocybin and Neurogenesis: How Psychedelics Grow New Brain Cells
The adult brain was supposed to stop growing new neurons. Psilocybin proved otherwise. Hippocampal neurogenesis surges after a single dose — the biological mechanism behind the antidepressant effect.
Psilocybin and Addiction: The Neuroscience of Breaking Chemical Dependency
80% 6-month smoking abstinence. 83% reduction in heavy drinking days. Psilocybin is producing addiction outcomes no pharmaceutical has matched. The neuroscience of why it works.
Psilocybin and Cluster Headaches: The Neuroscience of the World's Most Painful Condition
They call them suicide headaches — 10 attacks per day, each rated 10/10 pain. No pharmaceutical reliably stops them. Psilocybin does — even at sub-hallucinogenic doses.
Psilocybin and the Immune System: How Psychedelics Rewrite the Body's Inflammatory Code
Chronic inflammation drives depression, anxiety, neurodegeneration. Psilocybin targets the upstream immune switches directly — through receptors shared with T cells, macrophages, and microglia throughout the body.
Psilocybin and Sleep Architecture: The Neuroscience of Deep Sleep Restoration
Insomnia, fractured REM, and suppressed slow-wave sleep all share a common upstream driver — and psilocybin targets it directly. The emerging neuroscience of psychedelic sleep restoration.
Psilocybin and Chronic Pain: The Neuroscience of Breaking the Pain Cycle
Chronic pain rewires the brain's default mode network in the same way addiction does. Psilocybin may be the first compound that directly targets that architecture.
Psilocybin and Nicotine Addiction: The Neuroscience of Breaking Tobacco Dependence
80% abstinence at 6 months. Johns Hopkins' Matthew Johnson landmark trial rewrites what's possible for smoking cessation. Here is the full neuroscience.
Microdosing Psilocybin: What the Science Actually Says
Does microdosing psilocybin actually work? The most rigorous science — from TrkB-BDNF neuroplasticity to the Szigeti placebo trial — examined with full honesty.
Psilocybin and Neuroplasticity: How a Single Dose Rewires the Brain
A single psilocybin session triggers a 10% increase in dendritic spine density within 24 hours. The structural brain changes persist for weeks. Here is the neuroscience.
Psilocybin and Eating Disorders: The Neuroscience of Breaking Rigid Patterns
Anorexia has the highest mortality of any psychiatric disorder. New clinical trials show psilocybin disrupts the rigid neural patterns that drive eating disorders.
Psilocybin-Assisted Grief Therapy: Clinical Evidence for Healing Complicated Loss
80% of patients showed lasting reductions in grief and death anxiety. The clinical trial evidence for psilocybin-assisted therapy in prolonged grief disorder.
Psilocybin and Grief: The Neuroscience of Healing What Cannot Be Fixed
DMN hyperactivity, prolonged grief disorder, and four mechanisms by which psilocybin may help the brain complete what cannot be fixed.
Cognitive Flexibility and Executive Function Under Psilocybin
How psilocybin rebuilds the prefrontal cortex at the hardware level — REBUS, BDNF, and the 72-hour neuroplasticity window.
Ketamine vs Psilocybin: Two Molecules, Two Paths Out of Depression
Ketamine works in hours. Psilocybin works for months. A complete clinical comparison of the two most promising depression treatments in modern psychiatry.
Micro to Macro: The Science of Psilocybin Dosing Protocols
From 0.1g microdoses to 5g hero doses — five distinct tiers, their pharmacokinetics, and the clinical evidence behind the 25mg therapeutic standard. Griffiths 2016, COMPASS 2022, and the Fadiman vs Stamets debate.
Psilocybin and Alcohol Use Disorder: What the NEJM Trial Found
Bogenschutz 2022 in the New England Journal of Medicine: 83% reduction in heavy drinking days. Two psilocybin sessions restructured craving circuitry where 12 months of pharmacotherapy failed.
Why the Peak Experience Predicts Healing: The Science of the Mystical State
Griffiths' 2006 landmark trial showed that the degree of mystical experience directly predicted therapeutic outcome. The MEQ30 measures it. Here is the neuroscience behind why dissolution heals.
MDMA: The Molecule That Dissolves the Wall Between Self and Other
How MDMA floods the brain with serotonin, triggers a 2× oxytocin surge, silences the amygdala, and reopens a critical window for healing PTSD. The neuroscience behind 67% remission rates in phase 3 trials.
Psilocybin and OCD: Interrupting the Loop
OCD is a circuit problem, not a thought problem. The CSTC loop generates an error signal it cannot terminate. Three clinical trials now show psilocybin interrupts this loop via 5-HT2A activation — with a 73.3% responder rate and 40% full remission.
The Death-Anxiety Trials: Psilocybin and End-of-Life Existential Distress
Two landmark trials in 2016 found that a single psilocybin session produced clinically significant reductions in death anxiety in ~80% of terminal cancer patients. The effects lasted 4.5 years.
Psilocybin and PTSD: The Emerging Evidence
PTSD is not a memory problem — it is a fear extinction failure. New clinical trials are testing whether psilocybin can restore the neuroplasticity that the disorder destroys. The complete emerging science.
Anandamide: The Endocannabinoid That Cacao Unlocks
Your brain produces its own cannabinoid. Ceremonial cacao contains three FAAH-inhibiting compounds that block the enzyme that destroys it — extending the biology of bliss through a mechanism published in Nature in 1996.
Psilocybin and Creativity: What the Data Actually Shows
Controlled trials show psilocybin increases Openness to Experience by more than one standard deviation, persisting for 14 months. The complete neuroscience of creative cognition under psilocybin.
The Integration Window: How to Use the 72-Hour Neuroplasticity Period
BDNF is elevated for 72 hours after psilocybin. New synaptic connections form at measurable rates. What you do in this window determines whether the neuroplasticity produces lasting change — or fades.
MAO Inhibition in Cacao: The Amplification Mechanism
How ceremonial cacao’s β-carboline alkaloids reversibly inhibit monoamine oxidase — extending the life of serotonin, dopamine, and phenylethylamine.
The Inflamed Brain: How Psilocybin Resets the Immune-Neural Interface
Neuroinflammation silently drives depression, cognitive fog, and treatment resistance. How psilocybin modulates microglia, cytokines, and the IDO1 pathway to restore mental clarity.
The Vagus Nerve: Your Body’s Master Reset Button
How the vagus nerve regulates everything from mood to immune function — and why vagal tone is the hidden determinant of psychedelic healing depth.
Oxytocin, Psilocybin, and the Neuroscience of Social Connection
How psilocybin activates oxytocin pathways and dissolves the barriers to human connection — the receptor pharmacology of love, trust, and belonging.
Psilocybin and Depression: What Phase 3 Clinical Trials Actually Show
29% remission at 3 weeks vs 9% placebo. The COMPASS, Imperial College, and Johns Hopkins data — the most rigorous psychedelic trials ever conducted.
Ego Dissolution: The Neuroscience of Losing Yourself to Find Yourself
At high doses, psilocybin dismantles the neural architecture that constructs the experience of being a separate self. Imperial College London has mapped the mechanism.
Theobromine: The Heart-Opening Molecule
The primary alkaloid in ceremonial cacao isn't caffeine. Theobromine — a methylxanthine with a 6–10 hour half-life — dilates blood vessels, crosses the blood-brain barrier, and generates the warm, expansive state that defines the ceremonial cacao experience.
From Spore to Synapse: The Journey of Psilocybin Through Your Body
Psilocybin is pharmacologically inert. The active molecule is psilocin — and the 90-minute biochemical journey between ingestion and peak experience is one of the most precisely mapped stories in psychopharmacology.
The 5-HT2A Blueprint: How Psilocybin Speaks to Your Brain
The single receptor that explains psilocybin's profound transformation of consciousness — block it with one drug and the entire psychedelic experience disappears. The molecular blueprint decoded.
The Set and Setting Science: How Expectation and Environment Shape the Psilocybin Brain
Expectation, environment, and intention are not soft variables. They are pharmacologically active — shaping receptor binding, network dynamics, and long-term therapeutic outcomes in ways that clinical data now confirms.
Psilocybin and Addiction: Rewiring the Compulsive Brain
How 80% tobacco abstinence rates and 84% reductions in alcohol use are redefining what addiction treatment can achieve — and the precise neuroscience of why it works.
The Entropic Brain Hypothesis
How increased neural entropy during psychedelic states allows the brain to escape fixed attractor states and build new cognitive architectures.
Microdosing with Ceremonial Cacao: The Daily Integration Protocol
Sub-perceptual benefits of daily integration: improving divergent thinking and serotonergic baseline using ceremonial cacao as a psychedelic stack.
Psilocybin-Assisted Therapy for Combat Veterans
Three neurobiological mechanisms through which psilocybin addresses the structural brain changes caused by combat trauma — with clinical data from active veteran trials.
The Cacao-Psilocybin Synergy Protocol
Four neurochemical mechanisms through which ceremonial-grade cacao primes the nervous system and amplifies psilocybin's therapeutic effects.
BDNF and the Architecture of Neuroplasticity
How psilocybin triggers the release of brain-derived neurotrophic factor and physically rebuilds neural architecture at the synaptic level.
The Default Mode Network: Your Brain's Autopilot
Mapping the neural architecture that locks consciousness into repetitive thought patterns — and how psilocybin dissolves those fixed attractor states.
Your Brain on Psilocybin: The Complete Neuroscience of Neural Reconstruction
How psilocybin fundamentally rewrites the brain's operating system — the complete neuroscience of mystical experience, neuroplasticity, and lasting therapeutic change.